Mable
Genomics-based telehealth for personalised migraine care
Mable, operated by Neurolytic Healthcare Inc., is a telehealth platform that combines genomic and biomarker data with telemedicine to deliver personalized migraine treatment plans. Patients complete online consultations and DNA testing, and receive precision medicine recommendations tailored to their genetic profile. The platform provides ongoing virtual support to adjust treatments over time based on patient progress.
Patients complete an online consultation and DNA test, and Mable analyzes their genetic and biomarker data to generate a personalized migraine treatment plan delivered via telehealth.
Migraine sufferers seeking personalized, genomics-informed treatment
Background.
- Status
- unknown
- Business model
- unknown
- Company
- Neurolytic Healthcare, Inc.
- Launched
- 2019
Founders
- Inna Nicole Thalmann
- Roman Rothaermel
- Chris Eijsbouts
- Kumeren Govnder
Contact
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.